AFAnna Fenton

Anna Fenton

*This is an algorithmically generated author record based on publicly available information.

Anna Fenton has a total of 26 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Women’s and health professionals’ needs and preferences informing the updated IMS recommendations

    by A. J. Vincent, L. Yeganeh, A. Fenton, H. Hamoda, N. Panay

    Evidence underpinning recommendations for the health of midlife women (MW), including menopause hormone therapy (MHT), has evolved substantially over the past two decades. The 2016 International Me...

  • Open Access

    Changes in facial emotion processing and depression and anxiety symptoms with polycystic ovary syndrome treatment: a longitudinal, naturalistic study

    by Katie M. Douglas, Mayouri Sukhapure, Richard J. Porter, Anna Fenton, Kate Eggleston

    Purpose: Changes in facial emotion processing were examined over the course of anti-androgen treatment in women with PCOS. We also explored whether these changes in emotion processing correlated with changes in mood and anxiety symptoms over treatment. Methods: Thirty-three women with PCOS received 12 weeks of naturalistic treatment based on clinical presentation. Facial emotion processing was assessed at baseline and 12-weeks on the Reading the Mind in the Eyes Test, and a computerised Facial Expression Recognition (FER) Task, which measured accuracy and response time in recognising facial expressions (happiness, sadness, fear, disgust, anger, neutral), and neutral misinterpretation bias. The Hospital Anxiety and Depression Scale was completed at the same time-points. Outcomes were compared with a control group of 40 healthy women. Results: Women with PCOS (mean age = 29 years) were treated with a variety of medications, mainly spironolactone ( n = 22) and oral contraceptives ( n = 16). Within the PCOS group, significant improvement was found for 10 of 19 FER variables over treatment, and in depression and anxiety symptoms. When comparing the PCOS and control groups over time, the PCOS group became significantly faster in responding to disgusted and neutral expressions, and reduced in their tendency to misinterpret neutral faces as angry. Improved depression and anxiety symptoms correlated significantly with improved accuracy in recognising fearful expressions, but not with any other FER variables. Conclusions: In this preliminary study, anti-androgen treatment improved some aspects of facial emotion processing in women with PCOS, which has implications for understanding the mental health aspects of PCOS.


  • Top Cited Papers
    Open Access

    International Menopause Society (IMS) recommendations and key messages on women’s midlife health and menopause

    by Nick Panay, Anna Fenton, Haitham Hamoda, Timothy Hillard, Rakibul Islam, Hugo Pedder, Lorena Romero, Amanda J. Vincent

    Following a rigorous systematic review of the literature, the International Menopause Society (IMS) has produced detailed new recommendations and key messages on women's midlife health, menopause and menopause hormone therapy (MHT) to help guide healthcare professionals to optimize their management of women at this critical stage of life. The term MHT has been used to cover therapies including estrogens, progestogens and combined regimens. This guidance provides a summary of the recommendations and key messages generated from the systematic review process. The longer version, including the detailed text, key meta-analyses, references, figures and supplementary materials, will be published simultaneously online and can be accessed via the IMS website (https://www.imsociety.org/statements/ims-recommendations/). The quality of evidence and the strength of recommendations used in this guideline are based on the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) and the Appraisal of Guidelines for Research & Evaluation II (AGREE II) approaches. The new recommendations now include levels of evidence, grades of recommendations, good practice points and key messages. The recommendations were developed by a body of 38 authors and 26 support team members derived from the IMS and other organizations. Global stakeholder surveys, targeted at both healthcare providers and consumers, were initially conducted to identify the key questions. A Publication Steering Committee (PSC) provided oversight of the process through regular meetings and ensured consistency of methodology. By the end of the process, 30 completed sections were submitted by the authors to individual lead reviewers selected from the PSC to provide peer review and finally endorsed by the PSC, IMS board and stakeholders. Overall, 341 recommendations (285 supported by research data and 56 good practice points) and 38 key messages have been formulated. These span a diverse range of health topics, including lifestyle, midlife body changes, vasomotor symptoms, genitourinary syndrome of menopause, osteoporosis, cardiometabolic health, dementia, premature ovarian insufficiency and various malignancies. A new section addresses the often-overlooked topic of sarcopenia which requires urgent attention. Current controversial topics, such as the influence of the media, the role of the pharmaceutical industry and publication ethics, are also explored. The overall aim of these recommendations and guidelines is to provide the blueprint for the management of women's midlife health and menopause, given the latest available evidence. In preparing these international recommendations, experts have endeavored to consider geographical variations in medical care, prevalence of diseases/conditions, symptom severity, availability and licensing of MHT and alternatives, and country-specific attitudes of the public, medical community and health authorities toward menopause management.


  • Fat mass, weight and body shape changes at menopause – causes and consequences: a narrative review

    by A. Fenton, C. Smart, L. Goldschmidt, V. Price, J. Scott

    In addition to age-related weight gain, menopause adds additional challenges for women with the occurrence of significant metabolic alterations and central and visceral fat redistribution. The changes in body composition then influence risks of cardiovascular disease, metabolic disruption, cancer, fracture, lung disease, sexual dysfunction, mental health disorders and dementia. They may also heighten the severity of vasomotor symptoms. Treatment of these changes requires a flexible long-term strategy. This narrative review explores the pathogenesis of the metabolic changes at menopause and effective management options.


  • Open Access

    Changes in Mood, Anxiety, and Cognition with Polycystic Ovary Syndrome Treatment: A Longitudinal, Naturalistic Study

    by Mayouri Sukhapure, Kate Eggleston, Anna Fenton, Christopher Frampton, Richard J Porter, Katie M Douglas

    Purpose: Individuals with polycystic ovary syndrome (PCOS) are at increased risk of depression and anxiety symptoms and impairment in aspects of cognitive function. However, there is little evidence regarding effects of standard treatment for PCOS on these features of the syndrome. The aim of this study was to examine the effect of 12 weeks of naturalistic treatment of PCOS, with usual medications, on depression symptoms, anxiety symptoms and cognitive function. Patients and Methods: Thirty-three participants with PCOS received 12 weeks of individualised treatment based on clinical presentation. Changes in depression and anxiety symptoms were assessed with the self-report Hospital Anxiety and Depression Scale at baseline and 12 weeks, and cognitive function was assessed at the same time-points with a battery of tests spanning cognitive domains of verbal learning and memory, visuospatial learning and memory, psychomotor speed, attention and executive function. Outcomes were compared with a control group of 40 healthy participants. Results: Participants with PCOS (mean age = 29.2 years; mean Body Mass Index = 27.4) were treated with a variety of medications, predominantly spironolactone (n = 22) and oral contraceptives (n = 16). Depression and anxiety symptoms improved significantly over the course of treatment, with moderate effect sizes (Cohen’s d 0.43– 0.55, p < 0.05). Effect sizes of the difference in change from that of the control group were moderate but did not reach statistical significance. Women undergoing PCOS treatment demonstrated significant improvements in aspects of cognitive function, but improvement did not differ significantly from controls and effect size changes were similar, suggesting practise effects in both groups. Conclusion: Our study provides preliminary evidence that treatment of PCOS may be associated with improvement in psychiatric aspects of the syndrome, particularly depressive symptoms.


  • Menopause status and climacteric symptoms in a birth cohort of mid-life New Zealand women

    by G. F. H. McLeod, L. Cleland, J. Welch, J. K. Spittlehouse, A. Fenton, J. M. Boden, L. J. Horwood

    There is little current research on the transition to natural menopause among contemporary groups of mid-life women at age 40 years.This study reports on female members of the Christchurch Health a... 背景:目前几乎没有关于40岁中年女性向自然绝经过渡的研究。目的:这项研究报告了克赖斯特彻奇健康与发展研究队列中的女性成员。本研究旨在:记录40岁女性的绝经状况、生殖结果和更年期症状;检查绝经状态与同时测量的心理社会和经济福利之间的关系;并记录绝经状态和反映40岁前童年、家庭和个人因素的绝经潜在预测因素之间的联系。方法:克赖斯特彻奇健康与发展研究是一项纵向、有代表性的、前瞻性队列研究, 研究对...


  • Open Access

    Weight, Shape, and Body Composition Changes at Menopause

    by Anna Fenton

    Obesity and overweight are associated with increased risks of cardiovascular and metabolic disease and overall poor health outcomes. Menopause is associated with significant changes in body composition and the accumulation of peri-abdominal or visceral fat. Changes in energy expenditure and spontaneous activity have been noted. These mid-life changes can add further to the burden of obesity and its associated risks. An understanding of the role of estrogen, gonadotrophins, gut hormones, sleep deprivation and the microbiome is still rudimentary, but research will ultimately provide further targets for more effective management. This narrative review will explore the pathogenesis of body composition changes at menopause, the impact on health outcomes and therapeutic and management options.


  • Open Access

    Commentary on guidelines on menopause and postmenopausal osteoporosis: Indian menopause society

    by Anna Fenton

    Journal of Mid-life Health, Journal of Mid-life Health is official publication of the Indian Menopause Society

  • Time trends in breast cancer and menopause hormone therapy use in New Zealand

    by R. Farmer, A. Fenton

    Objective The publication of preliminary findings from the Women’s Health Initiative (WHI) Study in 2002 suggested an increased risk of breast cancer among users of menopause hormone therapy (MHT). This resulted world-wide in a rapid and significant decline in the use of hormone therapy. It was later claimed that breast cancer incidence rates had fallen as a result of lower rates of hormone therapy use. Our aim was to investigate whether there was an association between changes in the use of hormone therapy and rates of breast cancer diagnosis in New Zealand subsequent to the publication of the WHI. Method Validated prescription usage data along with breast cancer screening and cancer registration data were accessed. Time trends extending for 8 years after the publication of the WHI were assessed. Results The use of hormone therapy for managing menopausal symptoms fell by about 70% following the controversy about its safety. Breast cancer registration rates among women aged 50–59 years had started to fall in advance of this change in prescribing. Changes in other age groups appear to coincide with changes in the screening eligibility for the national breast screening program rather than use of hormone therapy. Conclusion The time trend analysis does not support an association between changes in hormone therapy use and the incidence rate of breast cancer.


  • Open Access

    Premature ovarian insufficiency: Pathogenesis and management

    by Anna J Fenton

    The term premature ovarian insufficiency (POI) describes a continuum of declining ovarian function in a young woman, resulting in an earlier than average menopause. It is a term that reflects the variable nature of the condition and is substantially less emotive than the formerly used "premature ovarian failure" which signaled a single event in time. Contrary to the decline in the age of menarche seen over the last 3-4 decades there has been no similar change in the age of menopause. In developed nations, the average age for cessation of menstrual cycles is 50-52 years. The age is younger among women from developing nations. Much has been written about POI despite a lack of good data on the incidence of this condition. It is believed that 1% of women under the age of 40 years and 0.1% under the age of 30 years will develop POI. Research is increasingly providing information about the pathogenesis and treatments are being developed to better preserve ovarian function during cancer treatment and to improve fertility options. This narrative review summarizes the current literature to provide an approach to best practice management of POI.